MedTrace Logo

Safety and Efficacy of Tocotrienols in Post-CABG Atrial Fibrillation

NCT03807037 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-08-25

No results posted yet for this study

Summary

This study is a prospective, randomized, controlled trial with parallel groups to assess the effects of tocotrienol in the occurrence of atrial fibrillation (AF) post-CABG.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tocotrienols

Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day

DRUG

Placebo oral capsule

Matching placebo to be administered orally at 1 capsule, twice daily

Sponsors & Collaborators

  • Institut Jantung Negara

    collaborator OTHER

  • Monash University Malaysia

    lead OTHER

Principal Investigators

  • Ahmad Farouk Musa, MD · Monash University Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807037 on ClinicalTrials.gov